Last reviewed · How we verify
NCT03699917
Goal-directed Fluid Therapy on Complications After Pancreaticoduodenectomy
trial in Pancreaticoduodenectomy in 64 participants. Completed in 31 July 2016.
31 July 2016
Quick facts
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 January 2015 |
| Primary completion | 31 July 2016 |
| Estimated completion | 31 July 2016 |
| Sites | 2 locations across United States |
Conditions studied
- Pancreaticoduodenectomy — all drugs for Pancreaticoduodenectomy →
- Stroke Volume Variation — all drugs for Stroke Volume Variation →
Sponsor
Wake Forest University Health Sciences
Who can join
18 and older, any sex, with Pancreaticoduodenectomy or Stroke Volume Variation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Optimal fluid balance is critical to minimize anastomotic edema in patients undergoing pancreaticoduodenectomy. This study examined the effects of decreased fluid administration on rates of postoperative pancreatic leak and delayed gastric emptying.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The impact of intraoperative goal-directed fluid therapy on complications after pancreaticoduodenectomy.
Sulzer JK, Sastry AV, Meyer LM, Cochran A, et al · · 2018 · cited 7× · PMID 30370053 · DOI 10.1016/j.amsu.2018.10.018
Verify or expand the search:
- PubMed search for NCT03699917
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreaticoduodenectomy
Currently open trials in the same condition.
- NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
- NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting
- NCT07412301 — The Effect of Celiac Axis Stenosis on Morbidity After Pancreatoduodenectomy - A Prospective Study · active not recruiting
- NCT06322680 — Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreatico · NA · recruiting
- NCT03785743 — Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma · NA · recruiting
Other Wake Forest University Health Sciences trials
Trials by the same sponsor.
- NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03699917 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
- Last refreshed: 23 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03699917.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing